论文部分内容阅读
目的探讨重型颅脑创伤患者应用依达拉奉治疗后血清白细胞介素(IL)-6、肿瘤坏死因子(TNF)-α水平的变化。方法选择重型颅脑创伤患者87例为研究对象,随机分成对照组42例和观察组45例。对照组给予常规治疗,观察组在对照组的基础上加用依达拉奉30mg/次,2次/d,比较两组患者治疗前后血清中TNF-α和IL-6水平变化。结果治疗后第7、14天观察组患者IL-6、TNF-α水平明显低于对照组;观察组预后良好率显著优于对照组,差异均有统计学意义(P<0.05)。结论依达拉奉能降低血清中TNF-α和IL-6的水平,减轻脑组织的炎性反应,促进脑组织神经功能恢复。
Objective To investigate the changes of serum interleukin (IL) -6 and tumor necrosis factor (TNF) -α in patients with severe traumatic brain injury treated with edaravone. Methods Eighty-seven patients with severe traumatic brain injury were selected and divided into control group (n = 42) and observation group (n = 45). The control group was given routine treatment. The observation group was given Edaravone 30mg / time, twice a day on the basis of the control group, and the changes of serum TNF-α and IL-6 levels in the two groups were compared before and after treatment. Results The levels of IL-6 and TNF-α in the observation group were significantly lower than those in the control group on the 7th and 14th days after treatment. The good prognosis of the observation group was significantly better than that of the control group (P <0.05). Conclusion Edaravone can reduce the level of TNF-α and IL-6 in serum, reduce the inflammatory reaction and promote the recovery of neural function in brain tissue.